Effects of a Lower Limb Strength Training Program on a Seated Robotic Device in Patients (Lambda_MIpil)

May 2, 2024 updated by: Institution de Lavigny

Effects of a Lower Limb Strength Training Program on a Seated Robotic Device in Subacute Acquired Brain Injury Patients: a Pilot Study.

The loss of lower limb strength that occurs after an Acquired Brain Injury (ABI) limits the patient's autonomy in participating in activities of daily living, including gait performance. In the sub-acute phase, it is difficult to implement a strengthening program, as weakness prevents exercise being performed with the recommended parameters. This limit can be exceeded by using specific robotic devices, which allow the effort provided to be adapted according to the patient's capacities. In addition, motivation can be improved by the use of feedback or incentive games. The aim of this pilot study is to obtain data on the effect of lower limb strength training with a seated robotic device in subacute ABI patients for a future larger randomised study. In addition, it aims to evaluate the recruitment rate, applicability, resources for implementation and patient tolerance to the training program.

Study Overview

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Vaud
      • Lavigny, Vaud, Switzerland, 1175
        • Institution de Lavigny

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Acquired Brain Injury of vascular, traumatic, infectious or tumoral origin in the subacute phase
  • Walking ability ≤ Functional Ambulatory Category level 5 (1-6)
  • Paresis of the lower limb: strength <57/100 on the Motricity Index
  • Cognitive and memory functions allowing the patient to follow treatment instructions and give informed consent

Exclusion Criteria:

  • Significant heart problem
  • Venous thrombosis less than 6 months
  • Musculoskeletal impairment not compatible with movement
  • Degenerative neurological disease
  • Oxygen-dependent
  • Blood pressure not stabilized

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: intervention group
group focus on lower limb strength training with a seated robotic device
2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training
Active Comparator: control group
physiotherapy group as usual, not focused on strength training
2x a week during 5 weeks, active physical therapy treatment based on movement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change from study inclusion to end of intervention at 5 weeks in strength of knee extensor's
Time Frame: Study inclusion to end of intervention at 5 weeks
measure with a manuel dynamometer, in newton
Study inclusion to end of intervention at 5 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change from study inclusion to end of intervention at 5 weeks in Motricity index legs
Time Frame: Study inclusion to end of intervention at 5 weeks
clinical manuel strength test, seating on a chair. From 0 to 33, 33 is normal strength.
Study inclusion to end of intervention at 5 weeks
change from study inclusion to end of intervention at 5 weeks in timed up and go
Time Frame: Study inclusion to end of intervention at 5 weeks
Mobility test: standing from a chair, walking 3 meters, turn around, returning and seat. in seconds
Study inclusion to end of intervention at 5 weeks
change from study inclusion to end of intervention at 5 weeks in 10 meters walk test
Time Frame: Study inclusion to end of intervention at 5 weeks
measure of mean gait speed on 10 meters, at comfortable and maximum gait speed. In meters/second.
Study inclusion to end of intervention at 5 weeks
change from study inclusion to end of intervention at 5 weeks in Ashworth Scale (spasticity)
Time Frame: Study inclusion to end of intervention at 5 weeks
measure of the resistance of a muscle to passive stretch according to REsistance to PASsive movement protocol. From 0 to 4, 4 is high spasticity.
Study inclusion to end of intervention at 5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Claude Pichonnaz, PhD, Haute Ecole de Santé Vaud

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 20, 2021

Primary Completion (Actual)

January 29, 2024

Study Completion (Actual)

January 29, 2024

Study Registration Dates

First Submitted

August 12, 2021

First Submitted That Met QC Criteria

August 18, 2021

First Posted (Actual)

August 25, 2021

Study Record Updates

Last Update Posted (Actual)

May 3, 2024

Last Update Submitted That Met QC Criteria

May 2, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2021-00721
  • 14-O20 (Other Grant/Funding Number: Commission scientifique du domaine santé HES-SO)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Group of strength training

Subscribe